United States Patent 12,472,172: Claim Scope, Dose-Titration Coverage, and HoFH Pediatric Landscape for Lomitapide
Executive summary: U.S. Patent 12,472,172 claims a pediatric dosing-titration regimen for lomitapide (and salts, including lomitapide mesylate) in homozygous familial hypercholesterolemia (HoFH) across age bands 5 to 10 and 11 to 15, plus dependent claim coverage on clinical lipid endpoints, genotype-like allele criteria, baseline LDL-C/xanthoma/cardiovascular status, and mandatory/optional adjunct diet or supplementation. It also contains a broader claim for pediatric hyperlipidemia with the same 5 to 10-year titration schedule. The competitive landscape centers on whether other patents claim (i) the same start dose, step sizes, step durations, and max daily doses, (ii) the same dietary fat-soluble vitamin supplementation regimen, and (iii) the same pediatric age stratification and label-like baseline inclusion criteria.
What is the claim structure and what does it cover?
The patent is method-based and claim coverage is driven by a core independent dosing algorithm plus dependent refinements.
Independent claim themes
1) HoFH pediatric dosing (age 5 to 10)
Claim 1 covers treating HoFH in pediatric patients aged 5 to 10 years by administering lomitapide (or pharmaceutically acceptable salt), with a staged regimen:
- Week ~0 to ~8: 2 mg/day
- Next ~4 weeks: titrate to 5 mg/day
- Next ~4 weeks: titrate to 10 mg/day
- Then: titrate up to max 20 mg/day
Core numeric elements in the independent claim:
- Start: 2 mg/day
- Step 1: 5 mg/day
- Step 2: 10 mg/day
- Max: 20 mg/day
- Time-on-dose segments: about 8 weeks, 4 weeks, 4 weeks (then open-ended titration from 10 mg/day to 20 mg/day)
2) HoFH pediatric dosing (age 11 to 15)
Claim 14 covers treating HoFH in pediatric patients aged 11 to 15 years by administering lomitapide with a staged regimen:
- Initial ~4 weeks: 2 mg/day
- Next ~4 weeks: titrate to 5 mg/day
- Next ~4 weeks: titrate to 10 mg/day
- Next ~4 weeks: titrate to 20 mg/day
- Then: titrate up to max 40 mg/day
Core numeric elements:
- Start: 2 mg/day
- Intermediate steps: 5, 10, 20 mg/day
- Max: 40 mg/day
- Time segments: about 4 weeks per step (through 20 mg/day), then open-ended titration to 40 mg/day
3) Pediatric hyperlipidemia dosing (age 5 to 10)
Claim 24 covers treating hyperlipidemia in pediatric patients aged 5 to 10 with the same regimen as Claim 1 (2 mg/day for ~8 weeks, then 5 mg/day for ~4 weeks, then 10 mg/day for ~4 weeks, then up to max 20 mg/day).
Dependent claim themes: endpoints, eligibility, salt/formulation, adjunct supplementation
Across both HoFH independent claims, the dependent claims add coverage axes that matter for infringement design-around and licensing.
Lipid reduction and target thresholds
- Claim 2: provides a reduction in LDL-C compared to baseline.
- Claim 3: provides reduction in LDL-C to <135 mg/dL.
- Claim 4: provides reductions across a broad lipid-panel set:
TC, apo B, non-HDL-C, VLDL-C, triglyceride, HDL-C (each compared to baseline).
These dependent claims anchor post-treatment lipid outcomes, which can become relevant if a generic or competitor follows a different titration schedule but still achieves these endpoints.
Stable lipid-lowering background therapy
- Claim 5: patient is on stable lipid-lowering therapy.
Specific adjunct supplementation package
- Claim 6: further comprises administering vitamin E, alpha-linolenic acid, linoleic acid, eicosapentaenoic acid, docosahexaenoic acid.
This is a concrete, testable “diet/supplement” element. If another regimen omits these, it can potentially avoid dependent claims, even if it uses the same titration backbone.
Salt and formulation
- Claim 7: lomitapide is lomitapide mesylate.
- Claim 8: lomitapide mesylate is encapsulated in a capsule.
These are narrower than the independent claims but can still constrain generic product designs if the prior art or bioequivalence strategy does not map to the same claimed form.
Genetic/allelic locus criteria
- Claim 9 (HoFH 5–10) and Claim 19 (HoFH 11–15): patient has at least 2 mutant alleles at LDLR, apo B, PCSK9, or LDLRAP1 gene loci.
This is an inclusion criterion based on genotype-like status. If a competitor treats without explicitly selecting patients meeting an “at least 2 mutant alleles” condition, it can reduce coverage risk for dependent claims.
Baseline LDL-C, xanthoma, and parental heterozygous criteria
- Claim 10 (5–10):
untreated LDL-C >500 mg/dL and cutaneous or tendon xanthoma before age 10, OR untreated LDL-C consistent with heterozygous familial hypercholesterolemia in both parents.
- Claim 11 (5–10):
treated LDL-C ≥300 mg/dL and xanthoma before 10, OR untreated LDL-C consistent with heterozygous FH in both parents.
- Claim 20 and Claim 21 (11–15): identical structures to Claims 10 and 11 respectively.
Cardiovascular status and untreated LDL-C thresholds
- Claim 12 (5–10): no documented cardiovascular disease and untreated LDL-C >160 mg/dL prior to administration.
- Claim 13 (5–10): established cardiovascular disease and LDL-C >130 mg/dL prior to administration.
- Claim 22 and Claim 23 (11–15): mirror Claims 12 and 13.
Dose coverage map (what is concretely claimed)
| Population / Claim |
Start dose |
Step 1 |
Step 2 |
Step 3 |
Step duration structure |
Max daily dose |
| HoFH, pediatric 5–10 (Claim 1) |
2 mg/day |
5 mg/day |
10 mg/day |
(to 20) |
~8 weeks at 2 mg, then ~4 weeks at 5 mg, then ~4 weeks at 10 mg, then titrate up to max |
20 mg/day |
| HoFH, pediatric 11–15 (Claim 14) |
2 mg/day |
5 mg/day |
10 mg/day |
20 mg/day |
~4 weeks at 2 mg, ~4 weeks at 5 mg, ~4 weeks at 10 mg, ~4 weeks at 20 mg, then titrate up |
40 mg/day |
| Pediatric hyperlipidemia 5–10 (Claim 24) |
2 mg/day |
5 mg/day |
10 mg/day |
(to 20) |
Same as Claim 1 |
20 mg/day |
The patent’s enforceable core is the titration schedule and maxima, especially the age-stratified max dose (20 mg for 5–10; 40 mg for 11–15).
How do the claims interact with typical HoFH and lomitapide treatment patterns?
Age banding is a central scope limiter
The patent distinguishes pediatric HoFH treatment by age with different duration at each step and different maximum dose ceilings:
- 5–10: max 20 mg/day
- 11–15: max 40 mg/day
That structure matters for both infringement and licensing: even if a regimen starts at 2 mg/day, a deviation in max dose or step timing can take it outside the literal scope of the independent claim.
The “about” language adds practical latitude
Claims use about for durations (e.g., “about 8 weeks”, “about 4 weeks”). That tends to broaden literal coverage around exact calendar cutoffs.
Dependent claims are tethered to clinical outcomes and patient selection
Dependent claims can become leverage points in dispute resolution. For example:
- A treatment that follows the same titration schedule but targets different LDL-C thresholds may still infringe independent claim coverage, while it may avoid dependent claim liability on LDL-C targets (<135 mg/dL).
- A regimen that differs in titration schedule but includes vitamin E and omega fatty acids may still be vulnerable on independent claims if the dosing matches.
What is the relevant “claim landscape” around lomitapide patents in the U.S.?
Without a full cited list of other U.S. patents in the prompt, a complete cross-reference cannot be produced. What can be done from the claim text alone is identify where competing patents usually cluster for lomitapide in HoFH and pediatrics, and which elements this patent most likely overlaps:
Overlap vectors most likely to create blocking or licensing pressure
-
Pediatric dosing/titration regimens
- Other families often claim dose initiation, titration frequency, and maximum dose limits in pediatric subsets.
- This patent’s distinct differentiator is the age-dependent max dose and step timing.
-
Adjunct dietary and supplementation packages
- The explicit inclusion of vitamin E and specific fatty acids makes this claim set more “operational” than a generic “dietary management” claim.
- Competing patents that cover alternative supplement profiles may avoid dependent claim scope.
-
Formulation (mesylate salt; encapsulated capsule)
- If another patent focuses on alternative formulations or delivery forms, it may fall outside Claims 7 and 8 even when using the same active ingredient.
-
Patient selection criteria
- Genotype-like inclusion (“at least 2 mutant alleles”) and LDL-C/xanthoma thresholds create a “who can be treated” gate that method claims often use to distinguish prior art.
What a competitor would try to change to reduce exposure
The patent’s independent claims are specifically constrained. Design-around efforts typically target:
- Max dose (20 mg/day vs 40 mg/day)
- Step schedule (duration per dose level)
- Age banding
- Supplement set (to escape dependent claims 6/16)
- Salt/formulation (to escape dependent claims 7/8/17/18)
- Patient inclusion criteria (to escape dependent genotype and baseline qualifiers)
Where does this patent sit within a “coverage stack” for HoFH pediatrics?
Independent claim breadth vs dependent claim narrowness
- The independent claims are broad on method and active ingredient and focus tightly on dosing steps and age bands.
- Dependent claims are narrow on lipid targets, supplementation list, allele criteria, and baseline inclusion.
Practically, enforcement leverage often concentrates on independent dosing regimens because they are easier to show in treatment records. Dependent claims matter when the schedule is close to the claimed one but details differ in supplements, endpoints, or eligibility.
Independent claim 24 extends beyond HoFH
Claim 24 covers pediatric hyperlipidemia (age 5 to 10) using the HoFH-like titration schedule. That can broaden use-case coverage in situations where clinicians or studies treat patients under a broader “hyperlipidemia” designation rather than HoFH designation.
What does the patent likely require to establish infringement?
For independent claims (Claims 1, 14, 24)
A plaintiff would generally need evidence that:
- The patient is in the claimed age band.
- The diagnosis aligns with the claimed indication (HoFH for Claims 1 and 14; “hyperlipidemia” for Claim 24).
- Lomitapide (or a salt) was administered with the claimed dose step sizes and time structure.
- The dosage reached the claimed maximum (or was titrated “up to” that maximum).
For dependent claims
The additional elements are typically record- or testing-dependent:
- LDL-C targets and lipid panel reduction (Claims 2-4)
- Stable lipid-lowering background therapy (Claim 5)
- Supplement/diet compound administration (Claim 6)
- Lomitapide mesylate capsule form (Claims 7-8)
- Allele counts at specified loci (Claim 9)
- Baseline LDL-C/xanthoma/cardiovascular status conditions (Claims 10-13)
Practical patent landscape implications for R&D and contracting
If you are developing a competing lomitapide program
- Small changes to titration schedules can matter if they change step timing and/or maximum dose.
- Changes to patient selection rules in protocols may avoid dependent claim exposure but usually do not help with independent claims if dosing is the same.
- Formulation changes can reduce dependent claim risk (mesylate capsule) but may not affect independent claim risk.
If you are negotiating licensing or freedom-to-operate
- The patent’s most license-sensitive elements are the dosing schedule and maximum dose by age band.
- The supplement package is a secondary but concrete lever for contract carve-outs.
Key Takeaways
- The patent’s enforceable core is a lomitapide pediatric titration regimen that is age-stratified with distinct maximum daily doses: 20 mg/day (age 5 to 10) and 40 mg/day (age 11 to 15).
- Dependent claims add operational constraints: vitamin E plus specified omega fatty acids, lomitapide mesylate capsule form, “at least 2 mutant alleles” at specified loci, and multiple baseline LDL-C/xanthoma/cardiovascular status criteria.
- Claim 24 expands beyond HoFH to pediatric hyperlipidemia (age 5 to 10) using the HoFH-like titration schedule.
- Competitive risk concentrates on whether other patents or products claim (or avoid) the same step sizes, step durations, and maxima, with secondary risk tied to the supplement package and patient selection criteria.
FAQs
-
What is the dosing schedule claimed for HoFH patients aged 5 to 10?
2 mg/day for about 8 weeks, then 5 mg/day for about 4 weeks, then 10 mg/day for about 4 weeks, then titrate to a maximum of 20 mg/day.
-
What is the dosing schedule claimed for HoFH patients aged 11 to 15?
2 mg/day for about 4 weeks, then 5 mg/day for about 4 weeks, then 10 mg/day for about 4 weeks, then 20 mg/day for about 4 weeks, then titrate to a maximum of 40 mg/day.
-
Does the patent cover lomitapide salts and a specific salt form?
Yes. It covers lomitapide or a pharmaceutically acceptable salt in the independent claims, and it narrows dependent coverage to lomitapide mesylate.
-
What adjunct supplementation is explicitly claimed?
The dependent claims require administration of vitamin E and the omega fatty acids alpha-linolenic acid, linoleic acid, eicosapentaenoic acid, and docosahexaenoic acid.
-
Is there a claim beyond HoFH?
Yes. The patent includes coverage for pediatric hyperlipidemia in age 5 to 10, using the same 2-5-10-then-20 mg/day titration framework.
References
[1] U.S. Patent 12,472,172 (claim set provided in prompt).
